ClinicalTrials.Veeva

Menu

Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

A

Asociación para Evitar la Ceguera en México

Status and phase

Terminated
Phase 3

Conditions

Diffuse Diabetic Macular Edema

Treatments

Procedure: Bevacizumab + Pars plana vitrectomy
Procedure: Bevacizumab + pars plana vitrectomy

Study type

Interventional

Funder types

Other

Identifiers

NCT00571142
APEC-ret

Details and patient eligibility

About

To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.

Enrollment

20 patients

Sex

All

Ages

25 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Older than 25 yo
  • Diffuse diabetic macular edema with or without previous treatment

Exclusion criteria

  • Another retinal disease
  • Pregnancy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 2 patient groups

1
Active Comparator group
Description:
Renal disease
Treatment:
Procedure: Bevacizumab + Pars plana vitrectomy
2
Active Comparator group
Description:
Without renal disease
Treatment:
Procedure: Bevacizumab + pars plana vitrectomy

Trial contacts and locations

1

Loading...

Central trial contact

Antonieta Burgoa; Veronica Kon-Jara, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems